Regeneron, Sanofi Amend License and Collaboration Agreement
Regeneron Pharmaceuticals and Sanofi have entered into the sixth amendment to their existing license and collaboration agreement.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results.
Regeneron Expands Sanofi Antibody Pact for $1B Upfront
Regeneron and Sanofi have amended their collaboration agreement for antibody development. Sanofi will pay Regeneron $1 billion upfront and up to $7 billion in potential milestone payments for co-development and co-commercialization of four new long-acting antibodies targeting IL-4, IL-13, IL-4Rα, and a bispecific IL-4x